Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

A new study of nerve cells affected by Huntington’s disease (HD) reveals that the disease-causing gene slowly expands over ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...